4. Discussion
NSAID-induced dyspepsia, osteoarthritis
OSTEOARTHRITIS, DUODENAL ULCERS
This randomized double-blind clinical trial was the first to compare the efficacy of a combination therapy of aceclofenac plus ilaprazole with celecoxib monotherapy for NSAID-induced dyspepsia. This study showed no significant intergroup difference in treatment efficacy or safety. Although there were no statistically significant differences in the outcome values, meaningful results were found for the clinical application of ilaprazole.Analysis of the PP set revealed that, while celecoxib monotherapy resulted in deterioration, combination therapy exhibited improved SF-LDQ scores at week 8 (As mentioned previously, celecoxib may be a good option for patients with NSAID-induced dyspepsia [The efficacy of ilaprazole for treating duodenal ulcers was demonstrated in several studies [The safety of ilaprazole has been demonstrated in several studies. Wang et al. conducted a study comparing ilaprazole doses of 5, 10, or 20 mg/day with a 20 mg/day dose of omeprazole, and they showed that ilaprazole was comparable to omeprazole and there were no clinically relevant changes in the hematology and biochemistry test results [This study had several limitations. First, despite planning a superiority test and setting a specific number of participants, no significant intergroup differences were found. A non-inferior clinical trial may be necessary. Second, the final number of study participants was small because of the high rate of scheduled-visit violations and loss of follow-up visits. However, as originally planned, the FA set included a sufficient number of patients. Third, most patients with symptomatic osteoarthritis typically use NSAIDs for a prolonged period. However, the follow-up duration in this study was only 8 weeks. Patients with osteoarthritis take NSAIDs for an extended period, necessitating a longer study period.